Related Experiment Videos
Single-agent immunosuppression after liver transplantation: what is possible?
Maria L Raimondo1, Andrew K Burroughs
1Liver Transplantation and Hepato-Biliary Medicine, Royal Free Hospital, Hampstead, London, UK.
Drugs
|July 12, 2002
Summary
Optimizing immunosuppression after liver transplantation is crucial. Steroid-free regimens and exploring single-drug therapies improve long-term outcomes by reducing drug toxicity and enhancing graft survival.
Area of Science:
- Immunology
- Transplantation Medicine
- Pharmacology
Background:
- Orthotopic liver transplantation success relies on immunosuppressive drugs, but these cause significant long-term adverse effects.
- Complications from immunosuppression are a leading cause of death in long-term survivors.
- The liver's 'immunological privilege' suggests potential for reduced immunosuppression.
Purpose of the Study:
- To review the evolution of immunosuppressive protocols in liver transplantation.
- To highlight strategies for reducing long-term drug-related morbidity and mortality.
- To discuss the potential for steroid-free and monotherapy regimens.
Main Methods:
- Review of current literature on immunosuppressive strategies in liver transplantation.
- Analysis of outcomes associated with different immunosuppressive protocols.
- Examination of the role of corticosteroids and calcineurin inhibitors.
Main Results:
- Withdrawal of corticosteroids is safe and reduces metabolic/cardiovascular complications.
- Steroid-free regimens are widely adopted and improve patient outcomes.
- Monotherapy, particularly with calcineurin inhibitors, shows promise for stable patients.
Conclusions:
- Evolving immunosuppressive protocols aim to minimize drug toxicity while maintaining graft survival.
- Steroid-free and single-drug strategies represent significant advancements in liver transplant management.
- Future research should focus on inducing allograft tolerance rather than broad immunosuppression.